360Dx

In Coronavirus Assay Validation for Emergency Use, Labs Encounter Multiple Pain Points

Mar 11, 2020

This story has been updated to include additional manufacturing capabilities of authorized reagent suppliers.

NEW YORK – Labs developing their own assays for SARS-CoV-2 virus detection in patients are coming across unexpected bottlenecks and hurdles as they rush toward US Food and Drug Administration emergency use authorization.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

In Coronavirus Assay Validation for Emergency Use, Labs Encounter Multiple Pain Points

To read the full story....

Breaking News

In Brief This Week: Thermo Fisher Scientific, Predictive Oncology, Myriad Genetics, and More

Qiagen Reports Preliminary Q2 Revenue Growth of 18 to 19 Percent

Diazyme Receives Emergency Use Authorization for Coronavirus Antibody Test

One of Four Coronavirus Antibody Tests Met UK Agency's Sensitivity Criteria in Head-to-Head Study

Curetis Gains Access to Additional €5 Million Debt Financing for COVID-19 R&D

FDA Grants EUAs for Enzo Life Sciences, Access Bio, Gene By Gene Coronavirus Tests

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

What's Popular?

BioMérieux Reports 62 Percent BioFire FilmArray Sales Growth in Preliminary Q2 Release

Amid Interest Generated by Coronavirus Testing, IPO Window Open for Dx Firms in 2020

FDA Letter Warns About False-Positive Results From Becton Dickinson SARS-CoV-2 Test

FDA Issues New Guidance for SARS-CoV-2 Pooled Sample Testing

Qiagen Reports Preliminary Q2 Revenue Growth of 18 to 19 Percent

Sponsorships